Companies › Jiangsu Genscend Biopharmaceutical
1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 1; Immunology; next expected readout Apr 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| GS101 injection IL-4 receptor alpha subunit antagonist | IL4R | Phase 3 | Atopic Dermatitis (AD) | Apr 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07411755 | GS101 injection | Phase 1 | Atopic Dermatitis (AD) | Immunology | Aug 2026 |
| NCT07386743 | GS101 injection | Phase 3 | Atopic Dermatitis (AD) | Immunology | Apr 2027 |
Apogee Therapeutics Pharvaris Netherlands AUG Therapeutics Lynk Pharmaceuticals Fujian Mindong Rejuvenation Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.